Search
for
Sort by
Research 30 of 140
- A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results
- Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers
- Maintenance, withdrawal, and re-treatment with ritlecitinib and brepocitinib in patients with alopecia areata in a single-blind extension of a phase 2a randomized clinical trial
- A phase 2a trial of brepocitinib for cicatricial alopecia
- 290 Brepocitinib improves cicatricial alopecia and downregulates key T-helper biomarkers
- 802 Molecular effect of brepocitinib in hidradenitis suppurativa (HS)
- Systematic review of newer agents for the management of alopecia areata in adults: Janus kinase inhibitors, biologics and phosphodiesterase‐4 inhibitors
- A review of Janus kinase inhibitor use in scarring alopecia
- Safety of Janus Kinase inhibitors in Patients with Alopecia Areata: A Systematic Review
- The relative efficacy of monotherapy with Janus kinase inhibitors, dupilumab and apremilast in adults with alopecia areata: Network meta‐analyses of clinical trials
- Adverse events in patients treated with Jak‐inhibitors for alopecia areata: A systematic review
- Alopecia areata: from pathophysiology to therapeutic innovation
- Alopecia Areata in Skin of Color Patients: New Considerations Sparked by the Approval of Baricitinib
- Use of Jak Inhibitors in the Treatment of Alopecia Areata
- LB1034 Meta-analysis of scalp transcriptome defines alopecia areata subtypes and molecular response to four (4) treatments with jak inhibiting properties
- Review of the 2024 American Academy of Dermatology (AAD) Annual Meeting
- Comparative efficacy and safety of JAK inhibitors in the treatment of moderate-to-severe alopecia areata: a systematic review and network meta-analysis
- 44182 Treatment with Oral Janus Kinase Inhibitors in Adults Patients with Alopecia Areata: A Systematic Review and Meta-Analysis
- Ritlecitinib: First Approval
- Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study
- Dupilumab induces hair regrowth in pediatric alopecia areata: a real-world, single-center observational study
- Comparative Efficacy and Safety of Janus Kinase Inhibitors Used in Alopecia Areata: A Systematic Review and Meta-analysis
- New small molecules in dermatology: for the autoimmunity, inflammation and beyond
- Efficacy and safety of different JAK inhibitors in the treatment of alopecia areata: a network meta-analysis
- Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development
- Moving Beyond Boundaries: Utilization of Longitudinal Exposure–Response Model for Bounded Outcome Score to Inform Decision Making in the Accelerated Drug Development Paradigm
- Janus kinase inhibitors for alopecia areata: a review of clinical data
- Safety of oral JAK inhibitors in treating alopecia areata: a systematic review and network meta-analysis
- Off-label use of biologics and janus kinase (JAK) inhibitors for scarring alopecias: a narrative review
- Korean Consensus Criteria for the Severity Classification of Alopecia Areata